10.21
Katherine Unger Baillie
Science News Officer
kbaillie@upenn.edu
Cancer Research
Algorithm personalizes which cancer mutations are best targets for immunotherapy
Algorithm personalizes which cancer mutations are best targets for immunotherapy
A new model developed by researchers in the Abramson Cancer Center hand-picks cancer cells to target for more effective, customized cancer vaccines.
In pursuit of a cure, when ideas and options have run out
In pursuit of a cure, when ideas and options have run out
A new book from Penn Medicine’s David Fajgenbaum chronicles his journey to beat Castleman disease, a rare disorder that he’s lived with for almost a decade.
Two studies highlight proton therapy for pediatric brain cancer
Two studies highlight proton therapy for pediatric brain cancer
A pair of new studies done at Penn and the Children’s Hospital of Philadelphia add to the growing body of research showing the potential benefits of proton therapy.
A potential new treatment for a deadly form of prostate cancer
A potential new treatment for a deadly form of prostate cancer
Blocking a specific protein sets off a chain reaction that results in the death of prostate cancer cells that have spread and are resistant to standard therapies.
Balance of ‘stop’ and ‘go’ signaling could be key to cancer immunotherapy
Balance of ‘stop’ and ‘go’ signaling could be key to cancer immunotherapy
A Penn study shows potential of the interferon pathway as a biomarker to help predict which patients are likely to respond to immunotherapies.
A new cancer drug, thanks to a new approach
A new cancer drug, thanks to a new approach
Researchers in the Abramson Cancer Center helped bring new hope to patients with multiple myeloma with a drug that targets the command center of a cancer cell.
Hormone therapy for prostate cancer may raise risk of Alzheimer’s, dementia
Hormone therapy for prostate cancer may raise risk of Alzheimer’s, dementia
A Penn study of more than 150,000 men with prostate cancer shows androgen deprivation therapy was associated with a higher likelihood of developing dementia when compared to patients who were not exposed to the treatment.
Shorter courses of proton therapy can be just as effective on prostate cancer
Shorter courses of proton therapy can be just as effective on prostate cancer
Treating prostate cancer with higher doses of proton therapy over a shorter amount of time leads to similar outcomes when compared to standard dose levels and treatments, and is safe for patients.
One simple change can reduce frequent cancer imaging by half
One simple change can reduce frequent cancer imaging by half
A “nudge” is helping shorten treatment time for patients with advanced cancer, with less frequent palliative radiation therapy sessions.
Elderly patients with metastatic renal cell carcinoma benefit from targeted therapies
Elderly patients with metastatic renal cell carcinoma benefit from targeted therapies
A Penn study of Medicare patients who are often underrepresented in medical trials finds overall survival benefits from treatment with targeted therapies.
Media Contact
Experts
In the News
HealthDay News
For Breast Cancer Patients, Less Time on Hormonal Meds?
Susan Domchek of the Perelman School of Medicine and the Abramson Cancer Center comments on hormonal therapy.
FULL STORY →
Nature
Acupuncture in Cancer Study Reignites Debate About Controversial Technique
Rollin Gallagher of the Perelman School of Medicine comments on a clinical trial that focused on whether acupuncture can relieve pain in cancer patients.
FULL STORY →